Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):102–104. doi: 10.1128/aac.40.1.102

Pharmacokinetics of cefetamet in plasma and skin blister fluid.

W Zimmerli 1, S Sansano 1, B Wittke 1
PMCID: PMC163065  PMID: 8787888

Abstract

Cefetamet pivoxil is an oral cephalosporin with enhanced affinity for the target penicillin-binding proteins 1 and 3 and an increased stability to beta-lactamases compared with older cephalosporins, such as cefalexin or cefaclor. The pharmacokinetics of cefetamet pivoxil was determined after the seventh and final dose of 500 mg of cefetamet pivoxil in eight healthy volunteers. Concentrations in plasma and cantharidin-induced skin blister fluid were determined by a high-performance liquid chromatography method. In addition, protein binding was assessed. Cmax was 4.8 +/- 1.7 micrograms/ml in skin blister fluid and 5.1 +/- 2.1 micrograms/ml in plasma. Tmax was delayed in skin blister fluid compared with plasma (3.9 +/- 1 versus 2.8 +/- 0.8 h; P < 0.001), and t1/2 was longer in skin blister fluid than in plasma (3.1 +/- 0.5 versus 2.3 +/- 0.3; P < 0.005). The mean percent penetration into cantharide blister fluid was 129% +/- 24% when measured as total drug and 149% +/- 28% when measured as free drug (P < 0.001). These data suggest that cefetamet has an excellent penetration into inflammatory interstitial fluid.

Full Text

The Full Text of this article is available as a PDF (200.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., KURZ H., SCHANKER L. S. The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther. 1960 Sep;130:20–25. [PubMed] [Google Scholar]
  2. Blouin R. A., Kneer J., Stoeckel K. Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. Antimicrob Agents Chemother. 1989 Mar;33(3):291–296. doi: 10.1128/aac.33.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blouin R. A., Stoeckel K. Cefetamet pivoxil clinical pharmacokinetics. Clin Pharmacokinet. 1993 Sep;25(3):172–188. doi: 10.2165/00003088-199325030-00002. [DOI] [PubMed] [Google Scholar]
  4. Bryson H. M., Brogden R. N. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1993 Apr;45(4):589–621. doi: 10.2165/00003495-199345040-00009. [DOI] [PubMed] [Google Scholar]
  5. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fassbender M., Lode H., Schaberg T., Borner K., Koeppe P. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis. 1993 May;16(5):646–653. doi: 10.1093/clind/16.5.646. [DOI] [PubMed] [Google Scholar]
  7. Hoogkamer J. F., Hesse W. H., Sansano S., Zimmerli W. Pharmacodynamic activity of a cephalosporin, Ro 40-6890, in human skin blister fluid: antibiotic activity in concert with host defense mechanisms. Antimicrob Agents Chemother. 1993 Dec;37(12):2622–2627. doi: 10.1128/aac.37.12.2622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kissling M. Cefetamet pivoxil in community-acquired pneumonia: an overview. Curr Med Res Opin. 1992;12(10):631–639. doi: 10.1185/03007999209111530. [DOI] [PubMed] [Google Scholar]
  9. Nye K., O'Neill P., Andrews J. M., Wise R. Pharmacokinetics and tissue penetration of cefprozil. J Antimicrob Chemother. 1990 May;25(5):831–835. doi: 10.1093/jac/25.5.831. [DOI] [PubMed] [Google Scholar]
  10. O'Neill P., Nye K., Douce G., Andrews J., Wise R. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrob Agents Chemother. 1990 Feb;34(2):232–234. doi: 10.1128/aac.34.2.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ohmori H., Kumon H., Kanemasa Y., Hirai Y., Saito T. [Study of finding the optimum dose of cefetamet pivoxil in complicated urinary tract infections]. Jpn J Antibiot. 1990 Dec;43(12):2102–2132. [PubMed] [Google Scholar]
  12. Stone J. W., Linong G., Andrews J. M., Wise R. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother. 1989 Feb;23(2):221–228. doi: 10.1093/jac/23.2.221. [DOI] [PubMed] [Google Scholar]
  13. Tam Y. K., Kneer J., Dubach U. C., Stoeckel K. Effects of timing of food and fluid volume on cefetamet pivoxil absorption in healthy normal volunteers. Antimicrob Agents Chemother. 1990 Aug;34(8):1556–1559. doi: 10.1128/aac.34.8.1556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tam Y. K., Kneer J., Dubach U. C., Stoeckel K. Pharmacokinetics of cefetamet pivoxil (Ro 15-8075) with ascending oral doses in normal healthy volunteers. Antimicrob Agents Chemother. 1989 Jun;33(6):957–959. doi: 10.1128/aac.33.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R., Bennett S. A., Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother. 1984 Jun;13(6):603–610. doi: 10.1093/jac/13.6.603. [DOI] [PubMed] [Google Scholar]
  16. Wise R., Gillett A. P., Cadge B., Durham S. R., Baker S. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 1980 Jul;142(1):77–82. doi: 10.1093/infdis/142.1.77. [DOI] [PubMed] [Google Scholar]
  17. Wise R. Methods for evaluating the penetration of beta-lactam antibiotics into tissues. Rev Infect Dis. 1986 Jul-Aug;8 (Suppl 3):S325–S332. doi: 10.1093/clinids/8.supplement_3.s325. [DOI] [PubMed] [Google Scholar]
  18. Wise R., Nye K., O'Neill P., Wostenholme M., Andrews J. M. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother. 1990 Jun;34(6):1053–1055. doi: 10.1128/aac.34.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wise R. The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):13–20. doi: 10.1093/jac/26.suppl_e.13. [DOI] [PubMed] [Google Scholar]
  20. Wyss R., Bucheli F. Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography. J Chromatogr. 1988 Aug 19;430(1):81–92. doi: 10.1016/s0378-4347(00)83136-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES